ARWR Arrowhead Pharmaceuticals, Inc. Stock Quote

ARWR [NASD]

Index	-	P/E	-	EPS (ttm)	-0.83	Insider Own	4.70%	Shs Outstand	102.34M	Perf Week	0.91%
Market Cap	8.80B	Forward P/E	-	EPS next Y	-0.92	Insider Trans	-9.13%	Shs Float	99.20M	Perf Month	5.13%
Income	-84.60M	PEG	-	EPS next Q	0.14	Inst Own	67.10%	Short Float	5.94%	Perf Quarter	66.61%
Sales	88.00M	P/S	99.99	EPS this Y	-221.80%	Inst Trans	0.24%	Short Ratio	5.47	Perf Half Y	71.16%
Book/sh	4.51	P/B	18.50	EPS next Y	-283.30%	ROA	-15.20%	Target Price	83.23	Perf Year	75.33%
Cash/sh	2.99	P/C	27.89	EPS next 5Y	7.33%	ROE	-17.40%	52W Range	19.51 - 86.75	Perf YTD	8.74%
Dividend	-	P/FCF	-	EPS past 5Y	12.10%	ROI	-20.20%	52W High	-3.82%	Beta	1.38
Dividend %	-	Quick Ratio	7.90	Sales past 5Y	196.80%	Gross Margin	-	52W Low	327.68%	ATR	3.71
Employees	98	Current Ratio	7.90	Sales Q/Q	-82.40%	Oper. Margin	-	RSI (14)	62.58	Volatility	4.11% 4.96%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-508.30%	Profit Margin	-96.10%	Rel Volume	0.60	Prev Close	82.15
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 23 AMC	Payout	-	Avg Volume	1.08M	Price	83.44
Recom	2.10	SMA20	4.47%	SMA50	14.39%	SMA200	68.64%	Volume	659,119	Change	1.57%

Dec-21-20

Downgrade

Robert W. Baird

Outperform → Neutral

$75

Dec-16-20

Initiated

UBS

Buy

$95

Nov-19-20

Initiated

Citigroup

Buy

$90

May-13-20

Initiated

RBC Capital Mkts

Outperform

$62

May-08-20

Upgrade

Oppenheimer

Perform → Outperform

$58

Apr-15-20

Upgrade

Cantor Fitzgerald

Neutral → Overweight

$55 → $60

Mar-24-20

Upgrade

SVB Leerink

Underperform → Mkt Perform

$29

Mar-17-20

Initiated

Goldman

Neutral

$45

Jan-21-20

Initiated

SVB Leerink

Underperform

$32

Dec-13-19

Initiated

Oppenheimer

Perform

Nov-29-19

Reiterated

Chardan Capital Markets

Buy

$45 → $81

Nov-27-19

Reiterated

B. Riley FBR

Buy

$59 → $83

Nov-25-19

Upgrade

Robert W. Baird

Neutral → Outperform

$70

Oct-24-19

Downgrade

Robert W. Baird

Outperform → Neutral

$39

Oct-22-19

Reiterated

Chardan Capital Markets

Buy

$32 → $45

Oct-03-19

Initiated

Robert W. Baird

Outperform

$39

Sep-07-18

Upgrade

B. Riley FBR

Neutral → Buy

$18 → $19

Sep-06-18

Reiterated

Chardan Capital Markets

Buy

$17.50 → $24.50

Aug-08-18

Reiterated

Cantor Fitzgerald

Overweight

$13 → $18

Jul-02-18

Reiterated

Chardan Capital Markets

Buy

$9.50 → $16

Jan-19-21 04:00PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2021 First Quarter Results Business Wire
Dec-19-20 09:18PM	Is ARWR A Good Stock To Buy Now According To Hedge Funds? Insider Monkey
Dec-07-20 04:10PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) Business Wire
06:38AM	ARWR: Update on Cardiometabolic Candidates Zacks Small Cap Research
Dec-02-20 08:00AM	NeuBase Therapeutics Announces Appointment of Curt Bradshaw, Ph.D. as Chief Scientific Officer GlobeNewswire
Nov-30-20 04:00PM	Arrowhead Pharmaceuticals to Participate in Upcoming Conferences Business Wire
Nov-28-20 01:23AM	New Forecasts: Here's What Analysts Think The Future Holds For Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Simply Wall St.
Nov-25-20 07:30AM	Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda Business Wire -5.58%
Nov-23-20 09:00PM	Arrowhead Pharmaceuticals, Inc (ARWR) Q4 2020 Earnings Call Transcript Motley Fool
05:21PM	Recap: Arrowhead Pharmaceuticals Q4 Earnings Benzinga
04:00PM	Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results Business Wire
02:15PM	Arrowhead Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Nov-13-20 10:00AM	Arrowhead Presents New Clinical Data on Cardiometabolic Pipeline at AHA 2020 Business Wire
09:00AM	Arrowhead Interim Clinical Data Demonstrate ARO-AAT Treatment Improved Multiple Biomarkers of Alpha-1 Liver Disease Business Wire
Nov-09-20 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming Conferences Business Wire
Nov-04-20 07:30AM	Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinars on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 Business Wire +8.19%
Nov-02-20 04:00PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Year End Results Business Wire
Oct-31-20 06:43AM	2 Monster Young Biotech Stocks to Add to Your Watchlist Motley Fool
Oct-15-20 05:00PM	Why Arrowhead Pharmaceuticals Stock Jumped Today Motley Fool +9.87%
04:12PM	Vertex Tumbles As It Stops Testing On Protein Deficiency Treatment Investor's Business Daily
10:24AM	Looking Into Arrowhead Pharmaceuticals's Return On Capital Employed Benzinga
Oct-14-20 05:29PM	Dow Jones Futures: Stimulus Deal Doubts Pause Stock Market Rally; Tesla, Nio Break Out; Fastly, Vertex Dive Late Investor's Business Daily
Oct-10-20 08:04AM	The Consensus EPS Estimates For Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Just Fell Dramatically Simply Wall St.
Oct-08-20 09:20AM	ARWR: Collaboration with Takeda for Co-Development and Co-Commercialization for ARO-AAT Zacks Small Cap Research
07:30AM	Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease Business Wire
Oct-06-20 10:46AM	Arrowhead Pharmaceuticals Inc. (ARWR) Fell Out Of Favor With Hedge Funds Insider Monkey
Sep-30-20 04:01PM	Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conference Business Wire
Sep-24-20 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) Business Wire
Sep-21-20 05:41AM	ARWR: Better Than Anticipated Interim Data for ARO-AAT Zacks Small Cap Research
Sep-17-20 11:28PM	Arrowhead Hits the Bullseye in Phase 2 Study of ARO-AAT; Analyst Targets Over 90% Upside TipRanks
Sep-16-20 04:24PM	Arrowhead Pharma Reveals Positive Data On Drug To Treat Liver Disease; ARWR Stock Jumps Investor's Business Daily +40.33%
11:48AM	Why Arrowhead Pharmaceuticals Stock Is Soaring Today Motley Fool
11:20AM	Why Arrowhead Pharma's Stock Is Trading Higher Today Benzinga
10:22AM	Looking Into Arrowhead Pharmaceuticals's Return On Capital Employed Benzinga
07:30AM	Arrowhead ARO-AAT Phase 2 Interim Results in Patients with Alpha-1 Liver Disease Demonstrate Improvements in Key Parameters after Six Months of Treatment Business Wire
Sep-10-20 10:37AM	ARWR: Encouraging Data Presented for Both ARO-APOC3 and ARO-ANG3 Zacks Small Cap Research
Sep-08-20 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming September 2020 Conferences Business Wire
07:30AM	Arrowhead Pharmaceuticals Appoints Oye Olukotun to Board of Directors Business Wire
Sep-07-20 07:01AM	Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Simply Wall St.
Aug-31-20 04:50AM	Arrowhead Presents Positive New Phase 1/2 Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at European Society of Cardiology Congress 2020 Business Wire
Aug-28-20 07:30AM	Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data on Investigational Hepatitis B Therapeutic JNJ-3989 at The Digital Liver Congress Business Wire
Aug-18-20 08:00AM	Arrowhead Pharmaceuticals to Participate in Upcoming August 2020 Conferences Business Wire
07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma Business Wire
Aug-11-20 07:30AM	Arrowhead Pharmaceuticals Initiates Dosing Phase 1/2 Study of ARO-ENaC for Treatment of Cystic Fibrosis Business Wire
Aug-10-20 07:15AM	ARWR: Biopsy Data from ARO-AAT Trial Before Year End 2020 Zacks Small Cap Research
Aug-05-20 04:00PM	Arrowhead Pharmaceuticals Reports Fiscal 2020 Third Quarter Results Business Wire
Jul-29-20 07:30AM	Arrowhead Pharmaceuticals Earns $20 Million Milestone Payment from Amgen for Start of Phase 2 Trial of AMG 890 Business Wire
Jul-28-20 07:08PM	3 Perfect 10 Stocks to Snap Up Now TipRanks -5.85%
11:59AM	Arrowhead Pharmaceuticals Hosts Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis Business Wire
Jul-24-20 04:10PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) Business Wire
Jul-18-20 07:17PM	Did Hedge Funds Make The Right Call On Arrowhead Pharmaceuticals Inc. (ARWR) ? Insider Monkey
Jul-09-20 08:19AM	What Kind Of Shareholders Hold The Majority In Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares? Simply Wall St.
07:30AM	Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis Business Wire
Jul-08-20 04:00PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Third Quarter Results Business Wire
10:13AM	Here's Why Arrowhead Pharmaceuticals Stock Jumped 34% in June Motley Fool
Jun-16-20 09:46PM	Is Arrowhead Pharmaceuticals Inc. (ARWR) A Good Stock To Buy? Insider Monkey +7.62%
09:30AM	ARWR: Multiple Shots on Goal for RNAi Platform Zacks Small Cap Research
Jun-02-20 12:35PM	Will Johnson & Johnson Acquire Arrowhead Pharmaceuticals? Motley Fool
May-30-20 06:35PM	Edited Transcript of ARWR earnings conference call or presentation 7-May-20 8:30pm GMT Thomson Reuters StreetEvents
May-28-20 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming June 2020 Conferences Business Wire
May-24-20 10:10AM	Is Arrowhead Pharmaceuticals a Buy? Motley Fool
May-22-20 11:34AM	Arrowhead Pharmaceuticals Is Likely to See a Trading Range Market Ahead TheStreet.com
May-19-20 07:02AM	Will Arrowhead Pharmaceuticals Be a Biotech Winner? Motley Fool
May-10-20 08:20AM	Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year Simply Wall St.
May-08-20 09:30PM	Arrowhead Pharmaceuticals, Inc (ARWR) Q2 2020 Earnings Call Transcript Motley Fool
May-07-20 04:00PM	Arrowhead Pharmaceuticals Reports Fiscal 2020 Second Quarter Results Business Wire
May-01-20 04:00PM	Arrowhead Pharmaceuticals to Participate in Upcoming May 2020 Conferences Business Wire -5.43%
04:00PM	Arrowhead Pharmaceuticals Announces Retirement of COO Bruce Given Business Wire
Apr-30-20 07:52AM	Is Arrowhead Pharmaceuticals Close to a Cure for HBV? Motley Fool -5.75%
Apr-22-20 07:30AM	Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Second Quarter Results Business Wire
Apr-20-20 06:31AM	Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Incredible 2370% Share Price Run Shows What Is Possible With Stocks Simply Wall St. +6.40%
Apr-10-20 07:30AM	Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-ENaC for Treatment of Cystic Fibrosis Business Wire
Apr-06-20 06:26PM	Alnylam, Dicerna Join Forces to Take on Arrowhead GuruFocus.com +10.80%
10:30AM	Former gene-silencing rivals bury the hatchet with new partnership American City Business Journals
Mar-20-20 02:15PM	Hedge Funds Have Never Been This Bullish On Arrowhead Pharmaceuticals, Inc. (ARWR) Insider Monkey +6.88%
Mar-18-20 08:00PM	Bragar Eagel & Squire is Investigating Certain Officers and Directors of comScore, Mammoth Energy, AMC Entertainment, and Arrowhead Pharmaceuticals and Encourages Investors to Contact the Firm GlobeNewswire -6.42%
Mar-17-20 04:10PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) Business Wire
04:10PM	Arrowhead Pharmaceuticals Announces Precautionary Measures to Mitigate Effects of Novel Coronavirus (COVID-19) Spread Business Wire
Mar-15-20 08:30AM	Is Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Salary Justified? Simply Wall St.
Mar-10-20 04:16PM	Bragar Eagel & Squire is Investigating Certain Officers and Directors of comScore, Zuora, AMC Entertainment, and Arrowhead Pharmaceuticals and Encourages Investors to Contact the Firm GlobeNewswire
Mar-03-20 07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-HSD in Normal Healthy Volunteers and Patients with NASH or Suspected NASH Business Wire
Mar-02-20 04:00PM	Arrowhead Pharmaceuticals to Participate in Upcoming March 2020 Conferences Business Wire
Feb-13-20 04:47PM	Bragar Eagel & Squire is Investigating Certain Officers and Directors of Zuora, Arrowhead Pharmaceuticals, ResMed, and Covetrus and Encourages Investors to Contact the Firm GlobeNewswire
Feb-12-20 09:37PM	Edited Transcript of ARWR earnings conference call or presentation 5-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Feb-07-20 09:36AM	Should First Trust Mid Cap Growth AlphaDEX ETF (FNY) Be on Your Investing Radar? Zacks
Feb-06-20 07:47AM	The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs Benzinga -5.99%
Feb-05-20 04:00PM	Arrowhead Reports Interim Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 Business Wire
04:00PM	Arrowhead Pharmaceuticals Reports Fiscal 2020 First Quarter Results Business Wire
07:43AM	The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data Benzinga
Feb-03-20 01:06PM	Arrowhead (ARWR) to Report Q1 Earnings: What's in the Cards? Zacks
Jan-24-20 05:31AM	Is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) A Volatile Stock? Simply Wall St.
Jan-22-20 04:29PM	Will These Biotechs Rival A Top-Notch Stock In High Triglycerides? Investor's Business Daily
07:30AM	Arrowhead Pharmaceuticals to Webcast Fiscal 2020 First Quarter Results Business Wire
Jan-21-20 04:30PM	Why This Top-Notch Biotech Stock Just Plunged By Double Digits Investor's Business Daily -15.65%
Jan-16-20 03:55PM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Arrowhead Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Jan-11-20 08:00AM	These Four Stocks Are In Buy Range Before Key Healthcare Conference Investor's Business Daily
Jan-10-20 11:51AM	3 Biotech Stocks to Bank on for Buyouts in 2020 InvestorPlace
Jan-06-20 07:30AM	Arrowhead Pharmaceuticals Appoints James Hassard as Chief Commercial Officer Business Wire
Jan-02-20 08:00AM	Biotech Stocks Are On Fire Who's Leading The Profit Pack For 2020? Investor's Business Daily
Dec-27-19 06:06PM	Best Stocks 2019: Innovation, As Usual, Wins The Day Or Even The Year Investor's Business Daily

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC, which is in Phase I/II clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GIVEN DOUGLAS B	Director	Jan 15	Sale	83.28	3,000	249,840	12,500	Jan 19 05:58 PM
Hamilton James C	Senior Vice President	Jan 14	Sale	81.29	10,000	812,942	126,250	Jan 15 05:49 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Jan 12	Sale	81.00	1,441	116,721	444,005	Jan 12 06:06 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Jan 11	Sale	81.02	11,597	939,589	445,446	Jan 12 06:06 PM
Hassard James	Chief Commercial Officer	Jan 07	Sale	75.00	15,625	1,171,875	109,375	Jan 08 06:05 PM
O'Brien Patrick	General Counsel	Jan 06	Sale	72.41	25,000	1,810,346	293,375	Jan 07 06:11 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Jan 06	Sale	72.44	30,625	2,218,477	457,043	Jan 07 06:08 PM
Hamilton James C	Senior Vice President	Jan 06	Sale	72.48	19,375	1,404,276	136,250	Jan 07 06:02 PM
Hamilton James C	Senior Vice President	Jan 05	Sale	72.53	19,375	1,405,303	155,625	Jan 07 06:02 PM
PERRY MICHAEL S	Director	Jan 04	Sale	76.09	4,000	304,360	90,000	Jan 05 06:14 PM
GIVEN DOUGLAS B	Director	Jan 04	Sale	76.08	4,000	304,320	119,368	Jan 05 06:11 PM
Waddill William D.	Director	Jan 04	Sale	76.08	3,750	285,300	30,250	Jan 05 06:01 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 18	Option Exercise	5.73	40,510	232,006	2,545,747	Dec 22 05:55 PM
GIVEN DOUGLAS B	Director	Dec 17	Sale	79.59	500	39,795	15,000	Dec 18 06:26 PM
GIVEN DOUGLAS B	Director	Dec 17	Sale	79.30	9,075	719,648	114,738	Dec 18 06:26 PM
Waddill William D.	Director	Dec 10	Sale	71.26	3,000	213,780	25,000	Dec 11 06:16 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 09	Option Exercise	2.01	38,676	77,739	2,543,913	Dec 10 07:07 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 09	Sale	69.06	38,676	2,670,805	2,505,237	Dec 10 07:07 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 08	Option Exercise	2.01	16,324	32,811	2,521,561	Dec 10 07:07 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 08	Sale	67.97	16,324	1,109,542	2,505,237	Dec 10 07:07 PM
Bradshaw Curt	Chief Scientific Officer	Nov 20	Sale	68.73	15,625	1,073,906	0	Nov 23 05:58 PM
Bradshaw Curt	Chief Scientific Officer	Nov 19	Sale	69.39	15,625	1,084,219	15,625	Nov 23 05:58 PM
San Martin Javier	Chief Medical Officer	Nov 19	Sale	69.39	19,500	1,353,105	130,500	Nov 20 06:03 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Nov 09	Option Exercise	14.54	43,505	632,563	471,173	Nov 12 05:49 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Nov 09	Sale	69.37	43,505	3,018,071	427,668	Nov 12 05:49 PM
Anzalone Christopher Richard	Chief Executive Officer	Oct 23	Sale	58.21	100,000	5,821,032	2,505,237	Oct 23 07:35 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Oct 20	Option Exercise	6.15	29,166	179,371	456,834	Oct 22 06:02 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Oct 20	Sale	54.04	29,166	1,576,131	427,668	Oct 22 06:02 PM
Ferrari Mauro	Director	Oct 09	Sale	48.00	10,000	480,000	30,971	Oct 13 06:01 PM
De Backer Marianne	Director	Oct 08	Buy	50.47	1,000	50,465	17,500	Oct 26 06:02 PM
Anzalone Christopher Richard	Chief Executive Officer	Aug 13	Option Exercise	9.90	50,000	495,000	2,655,237	Aug 14 06:08 PM
Anzalone Christopher Richard	Chief Executive Officer	Aug 13	Sale	41.35	50,000	2,067,500	2,605,237	Aug 14 06:08 PM
Anzalone Christopher Richard	Chief Executive Officer	Jun 25	Sale	38.81	100,000	3,881,017	2,605,237	Jun 26 06:02 PM
De Backer Marianne	Director	Jun 15	Buy	31.33	500	15,665	16,500	Jun 24 06:10 PM
PERRY MICHAEL S	Director	May 14	Option Exercise	3.70	77,000	285,200	85,000	May 18 06:27 PM
PERRY MICHAEL S	Director	May 12	Sale	35.83	36,000	1,289,891	8,000	May 13 06:48 PM
Waddill William D.	Director	May 11	Sale	36.54	26,000	950,040	28,000	May 13 06:45 PM
GIVEN BRUCE D	Chief Operating Officer	Apr 28	Option Exercise	8.61	4,197	36,131	855,831	Apr 29 07:19 PM
GIVEN BRUCE D	Chief Operating Officer	Apr 28	Sale	40.00	5,101	204,040	850,730	Apr 29 07:19 PM
GIVEN BRUCE D	Chief Operating Officer	Apr 27	Option Exercise	5.19	200	1,038	851,934	Apr 29 07:19 PM
GIVEN BRUCE D	Chief Operating Officer	Apr 27	Sale	40.00	300	12,000	851,634	Apr 29 07:19 PM
GIVEN BRUCE D	Chief Operating Officer	Apr 20	Option Exercise	8.14	16,256	132,286	875,249	Apr 22 07:00 PM
GIVEN BRUCE D	Chief Operating Officer	Apr 20	Sale	40.00	23,515	940,600	851,734	Apr 22 07:00 PM
De Backer Marianne	Director	Apr 15	Buy	35.40	500	17,700	16,000	Jun 24 06:10 PM
GIVEN DOUGLAS B	Director	Apr 14	Sale	36.89	25,000	922,250	155,925	Apr 16 07:47 PM
De Backer Marianne	Director	Mar 16	Buy	23.94	500	11,970	15,500	Jun 24 06:10 PM
De Backer Marianne	Director	Mar 12	Buy	24.80	500	12,400	15,000	Jun 24 06:10 PM
De Backer Marianne	Director	Mar 11	Buy	28.60	500	14,300	14,500	Jun 24 06:10 PM
De Backer Marianne	Director	Feb 28	Buy	34.39	500	17,195	14,000	Jun 24 06:10 PM
De Backer Marianne	Director	Feb 27	Buy	35.07	500	17,535	13,500	Jun 24 06:10 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Feb 25	Option Exercise	8.84	43,445	384,145	427,668	Feb 27 05:41 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience